TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02681081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Administration
Description: For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting
Description: For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Normal food intake
Study: NCT02606318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjusted the challenge-skill balance
Description: In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Non-adjusted the challenge-skill balance
Description: The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
Study: NCT01541865

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal Denervation
Description: percutaneous renal denervation using the Vessix RF balloon catheter
Study: NCT03046836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU oxytocin nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT01476410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Optional correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Optional correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Optional correlative studies
Study: NCT03141255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVTM™ System
Description: TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quattro® Catheter
Description: TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
Study: NCT02240121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin EIR
Description: Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study: NCT02213068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention

Intervention type: DRUG
Group type: OTHER
Intervention: MPA
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
Study: NCT02797912

Intervention type: OTHER
Intervention: No intervention
Study: NCT01655238

Intervention type: OTHER
Intervention: BMI
Description: Screening guideline to assess body mass index.
Study: NCT04137419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Description: Probiotic strains

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to ProlacSan lozenges in taste in colour
Study: NCT03764579

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep and diet intervention vs diet intervention
Description: lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep and diet intervention vs diet intervention
Description: lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
Study: NCT04586556

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polyps detection by Artificial Intelligence
Description: The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
Study: NCT02111512

Intervention type: DRUG
Group type: OTHER
Intervention: Administration of Live attenuated influenza vaccine (LAIV)
Study: NCT04228562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-modifiable factor
Description: the presence of an uncontrollable / unremovable risk factor for a disease

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-modifiable factor
Description: the presence of an uncontrollable / unremovable risk factor for a disease
Study: NCT00158756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for the Rotarix™ vaccine
Study: NCT02067143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prephase PDN + CY
Study: NCT00158756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for the Rotarix™ vaccine
Study: NCT01319773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion Formulation A
Description: One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion Formulation B
Description: One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%
Description: One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%
Description: One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Description: One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
Study: NCT03822832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study: NCT04023903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules
Study: NCT01145430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04158661

Intervention type: PROCEDURE
Intervention: thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)
Description: preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).

Intervention type: PROCEDURE
Intervention: thymectomy by means of median sternotomy (transsternal)
Description: with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).

Intervention type: PROCEDURE
Intervention: no thymectomy (control)
Description: routine medical care
Study: NCT02775474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of Intraoperative Intravenous Methadone
Description: The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Intraoperative Intravenous Fentanyl
Description: The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
Study: NCT03663439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified shell technique
Description: divided block of bone into two shells and grafting one shell in anterior maxilla

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified shell technique
Description: divided block of bone into two shells and grafting one shell in anterior maxilla
Study: NCT01551225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
Study: NCT01335386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLYX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine
Study: NCT02694471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical inactivity or bed rest with supervised recovery
Description: All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical inactivity or bed rest with supervised recovery
Description: All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
Study: NCT02683265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT01102374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D
Description: Vitamin D3 100,000 IU monthly
Study: NCT02067143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 1 Induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 2 Induction / Early consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 3 Early consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 4 Consolidation
Study: NCT04228562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of anticipated regret
Description: higher level of elaboration on potential regret

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induction of anticipated regret
Description: higher level of elaboration on potential regret
Study: NCT03332303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace® Cream
Description: Estrace® Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Cream
Description: Estradiol Vaginal Cream
Study: NCT01102374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Vitamin D
Description: Vitamin D 12,000 IU monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo monthly

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Study: NCT03332303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle Cream
Study: NCT02213822

Intervention type: OTHER
Intervention: Molecular Analysis of Cancer
Description: The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
Study: NCT01884961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost of radiotherapy + high dose IL-2 treatment
Description: Boost of radiotherapy + high dose IL-2 treatment
Study: NCT02452177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT00526461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: IV
Study: NCT01332604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Intravenous repeating dose
Study: NCT00807300

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided brachytherapy
Description: catheter placed into the tumor by CT-guidance, radiation with iridium 192

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transarterial chemoembolization
Description: application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
Study: NCT02205918

Intervention type: OTHER
Intervention: Active TMS
Description: There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS.

Intervention type: OTHER
Intervention: Sham TMS
Description: There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS.
Study: NCT03626740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
Study: NCT02067143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 5 Consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 6 Consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 7 Consolidation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 8 Reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: If MRD negative MRD u/k SR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic SCT or Autologous SCT
Description: If MRD positive MRD u/k HR
Study: NCT02041299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Study: NCT04254146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
Study: NCT01313910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunolin®
Description: Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
Study: NCT02172391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation powder capsules
Study: NCT01102374

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Study: NCT01125657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT02172391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder capsules
Study: NCT04163978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: in situ 240mL nitric oxide releasing sinus irrigation solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Saline based sinus irrigation 1mg Budesinide solution
Study: NCT02869334

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation (tDCS)
Description: Sham (inactive or placebo) tDCS
Study: NCT04913480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
Study: NCT03815149

Intervention type: DEVICE
Intervention: Pipeline™ Flex Embolization Device with Shield Technology™
Description: Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.